Immuneering annual shares outstanding
2022
2023
2024
2025
Immuneering Shares Outstanding History (IMRX)
Immuneering reported 64.6M shares outstanding at the end of fiscal 2025.
View full Immuneering company overviewImmuneering annual shares outstanding history
| Fiscal year | Period ended | Shares outstanding | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | 64.6M | 33.6M | +108.20% |
| 2024 | 2024-12-31 | 31.1M | 1.8M | +6.08% |
| 2023 | 2023-12-31 | 29.3M | 2.9M | +10.80% |
| 2022 | 2022-12-31 | 26.4M | — | — |
Immuneering quarterly shares outstanding
Q2.21
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Shares outstanding | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | 64.7M | 28.7M | +79.78% |
| Q1 2026 | 2026-03-31 | 64.7M | — | — |
| Q4 2025 | 2025-12-31 | 64.6M | — | — |
| Q3 2025 | 2025-09-30 | 63.5M | — | — |
| Q2 2025 | 2025-06-30 | 36.0M | — | — |
| Q2 2021 | 2021-06-30 | 25.9M | — | — |
Immuneering shares outstanding trends
Between the periods ended 2022-12-31 and 2025-12-31, Immuneering's shares outstanding moved from 26.4M to 64.6M, a change of 38.2M. The latest reported quarter, Q2 2026, shows 64.7M.
About the metric
What shares outstanding means
Shares outstanding is the number of common shares held by investors at a reporting-period end. The count can change because of stock issuance, repurchases, conversions, acquisitions, or stock splits.
Calculation and source
SEC-reported period-end shares
TickerStat displays period-end common shares from SEC filings and adjusts older values to the current share basis when a stock-split conversion ratio is reported directly or evidenced by a later filing’s restated historical share balance. After repeated reverse splits, an old period can represent less than one current-basis share; this is a split-adjusted equivalent, not a literal historical certificate count. Values remain as reported when no reliable split ratio is available. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Immuneering source filings ↗